~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Israeli drug developer Pluristem Therapeutics Inc. last week announced that the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the US National Institutes of Health (NIH), will initiate studies in large animals to evaluate dosing for Pluristem’s PLX-R18 as a medical counter measure in the treatment of the hematologic components of Acute Radiation Syndrome (ARS).
Pluristem Therapeutics Inc.
The company has developed an anti-radiation therapy that the US government is eager to purchase, because it cures 100% of cases of exposure to radiation. Acute Radiation Syndrome is caused by exposure to very high levels of radiation, such as those that could occur in a nuclear catastrophe. The syndrome can cause severe illness or death.
Continue reading about this procedure, and about US aid to a corrupt Palestinian leadership
